Grants per year
Dr. Rich has a career interest in understanding the causes and treatments of pulmonary hypertension. He was principle investigator for the NIH Registry on Primary Pulmonary Hypertension, the first of its kind, and has been the leader of the largest clinical center in the USA for evaluating and treating patients with pulmonary hypertension since 1980. Dr. Rich has conducted pioneering research on the molecular mechanisms, epidemiology, clinical presentation, natural history and treatments of the disease. This knowledge has lead to the discovery of more effective treatments for pulmonary hypertension, including the use of medicines like anticoagulants, calcium channel blockers, and prostacyclins. His pioneering research has led to a greater understanding of all types of pulmonary hypertension.
Dr. Rich is currently involved with novel drug and device development to treat advanced pulmonary hypertension and right heart failure. This includes disease modifying drugs for pulmonary arterial hypertension, a first-in-man for pulmonary hypertension associated with heart failure with preserved function, and a durable right ventricular assist device. In addition, he is a collaborator with the World Health Organization Global Burden of Disease initiative and the newly initiated pulmonary hypertension project.
He has expanded the Pulmonary Vascular Disease Program at Northwestern to now offer every approved intervention for patients, including every approved medicine, interventional procedures, surgical pulmonary endarterectomy, and lung transplantation. He also has created an alliance with the Pulmonary Hypertension Program at Lurie Children's Hospital to now offer clinical services to any patient with pulmonary hypertension of any age.
|1976||Internship, Washington University in St Louis, Barnes Jewish Hospital|
|1978||Residency, Washington University in St Louis, Barnes Jewish Hospital|
|1980||Fellowship, University of Chicago Hospitals|
Expertise related to UN Sustainable Devlopment Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
MD, Loyola University/Stritch School of Medicine
… → 1974
- Adult Congenital Heart Disease
- Cardiovascular Diseases
- Clinical Research
- Clinical Trial Methodology
- Critical Cardiac Care
- Drug Discovery
- Heart Failure
- Pulmonary Hypertension
- 1 Similar Profiles
Dive into details
Select a country/territory to view shared publications and projects
Prot#LTI-302: A Global, Open-Label, Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Inhaled LIQ861(Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients
4/29/19 → 4/29/22
Project: Research project
Prot# PULSE-PAH-004: A Phase 3, Placebo Controlled, Double-blind, Randomized, Clinical Study to Determine Efficacy, Safety and Tolerability of Pulsed, Inhaled Nitric Oxide (iNO) versus Placebo in Symptomatic Subjects with Pulmonary Arterial Hypertension (
11/2/16 → 11/2/19
Project: Research project
Changes in Stressed Blood Volume with Levosimendan in Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction: Insights Regarding Mechanism of Action From the HELP TrialBrener, M. I., Hamid, N. B., Sunagawa, K., Borlaug, B. A., Shah, S. J., Rich, S. & Burkhoff, D., Sep 2021, In: Journal of Cardiac Failure. 27, 9, p. 1023-1026 4 p.
Research output: Contribution to journal › Article › peer-review
Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute WorkshopLeopold, J. A., Kawut, S. M., Aldred, M. A., Archer, S. L., Benza, R. L., Bristow, M. R., Brittain, E. L., Chesler, N., Deman, F. S., Erzurum, S. C., Gladwin, M. T., Hassoun, P. M., Hemnes, A. R., Lahm, T., Lima, J. A. C., Loscalzo, J., Maron, B. A., Mercer Rosa, L., Newman, J. H., Redline, S. & 10 others, , 2021, (Accepted/In press) In: Circulation: Heart Failure. p. 725-733 9 p., e007975.
Research output: Contribution to journal › Review article › peer-review
Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP TrialBurkhoff, D., Borlaug, B. A., Shah, S. J., Zolty, R., Tedford, R. J., Thenappan, T., Zamanian, R. T., Mazurek, J. A., Rich, J. D., Simon, M. A., Chung, E. S., Raza, F., Majure, D. T., Lewis, G. D., Preston, I. R. & Rich, S., May 2021, In: JACC: Heart Failure. 9, 5, p. 360-370 11 p.
Research output: Contribution to journal › Article › peer-reviewOpen Access
Hansmann, G., Rich, S. & Maron, B. A., Oct 2020, In: Cardiovascular Diagnosis and Therapy. 10, 5, p. 1718-1724 7 p.
Research output: Contribution to journal › Comment/debate › peer-reviewOpen Access
Dual-Energy Computed Tomography as an Alternative Noninvasive Study for Evaluation of Chronic Thromboembolic Pulmonary Hypertension PostoperativelyDesai, A., Malaisrie, S. C., Cuttica, M., Freed, B. H., Rich, S., Schimmel, D. & Avery, R., May 1 2020, In: Circulation: Cardiovascular Imaging. 13, 5
Research output: Contribution to journal › Comment/debate › peer-review